Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors
- PMID: 20171895
- DOI: 10.1016/j.bmc.2010.01.060
Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors
Abstract
Histone deacetylases (HDACs) are enzymes involved in tumor genesis and development. Herein, we report a novel series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as HDACs inhibitors. The preliminary biological screening showed that most of our compounds exhibited potent inhibitory activity against HDACs. Within this series, five compounds, 13a (IC(50)=0.58+/-0.10 microM), 7d (IC(50)=1.00+/-0.16 microM), 8l (IC(50)=1.06+/-0.14 microM), 7i (IC(50)=1.17+/-0.19 microM) and 7a (IC(50)=1.29+/-0.15 microM) possessed better HDACs inhibitory activity than Vorinostat (IC(50)=1.48+/-0.20 microM). So these five compounds could be used as novel lead compounds for further design of HDACs inhibitors. The anti-proliferative activities of a few compounds and the structure-activity relationships are also briefly discussed.
Copyright 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
New aryldithiolethione derivatives as potent histone deacetylase inhibitors.Bioorg Med Chem. 2010 Jun 15;18(12):4187-94. doi: 10.1016/j.bmc.2010.05.011. Epub 2010 May 7. Bioorg Med Chem. 2010. PMID: 20576572
-
Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.Bioorg Med Chem. 2011 Aug 1;19(15):4437-44. doi: 10.1016/j.bmc.2011.06.046. Epub 2011 Jun 21. Bioorg Med Chem. 2011. PMID: 21733698
-
Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.J Med Chem. 2011 Apr 28;54(8):2823-38. doi: 10.1021/jm101605z. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21476600
-
Identification of type-specific anticancer histone deacetylase inhibitors: road to success.Cancer Chemother Pharmacol. 2010 Sep;66(4):625-33. doi: 10.1007/s00280-010-1324-y. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2010. PMID: 20401613 Review.
-
[Structure-activity relationships of histone deacetylase inhibitors].Yao Xue Xue Bao. 2009 Oct;44(10):1072-83. Yao Xue Xue Bao. 2009. PMID: 20055127 Review. Chinese.
Cited by
-
Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study.RSC Adv. 2013 Nov 21;3(43):10.1039/C3RA43249A. doi: 10.1039/C3RA43249A. RSC Adv. 2013. PMID: 24273644 Free PMC article.
-
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3. Future Med Chem. 2012. PMID: 22416777 Free PMC article. Review.
-
Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity.Chem Biol Drug Des. 2013 Aug;82(2):125-30. doi: 10.1111/cbdd.12144. Epub 2013 Jul 1. Chem Biol Drug Des. 2013. PMID: 23581848 Free PMC article.
-
Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.Eur J Med Chem. 2012 Aug;54:771-83. doi: 10.1016/j.ejmech.2012.06.032. Epub 2012 Jun 23. Eur J Med Chem. 2012. PMID: 22770607 Free PMC article.
-
Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling.Mol Divers. 2024 Aug;28(4):2197-2215. doi: 10.1007/s11030-024-10903-y. Epub 2024 Jun 13. Mol Divers. 2024. PMID: 38871969
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information